Kimand Soo-Kyung, Jacobson Kenneth A
Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, Maryland 20892, USA.
J Chem Inf Model. 2007 May-Jun;47(3):1225-33. doi: 10.1021/ci600501z. Epub 2007 Mar 6.
The binding affinity and relative maximal efficacy of human A3 adenosine receptor (AR) agonists were each subjected to ligand-based three-dimensional quantitative structure-activity relationship analysis. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) used as training sets a series of 91 structurally diverse adenosine analogues with modifications at the N6 and C2 positions of the adenine ring and at the 3', 4', and 5' positions of the ribose moiety. The CoMFA and CoMSIA models yielded significant cross-validated q2 values of 0.53 (r2 = 0.92) and 0.59 (r2 = 0.92), respectively, and were further validated by an external test set (25 adenosine derivatives), resulting in the best predictive r2 values of 0.84 and 0.70 in each model. Both the CoMFA and the CoMSIA maps for steric or hydrophobic, electrostatic, and hydrogen-bonding interactions well reflected the nature of the putative binding site previously obtained by molecular docking. A conformationally restricted bulky group at the N6 or C2 position of the adenine ring and a hydrophilic and/or H-bonding group at the 5' position were predicted to increase A3AR binding affinity. A small hydrophobic group at N6 promotes receptor activation. A hydrophilic and hydrogen-bonding moiety at the 5' position appears to contribute to the receptor activation process, associated with the conformational change of transmembrane domains 5, 6, and 7. The 3D-CoMFA/CoMSIA model correlates well with previous receptor-docking results, current data of A3AR agonists, and the successful conversion of the A3AR agonist into antagonists by substitution (at N6) or conformational constraint (at 5'-N-methyluronamide).
对人A3腺苷受体(AR)激动剂的结合亲和力和相对最大效能分别进行基于配体的三维定量构效关系分析。比较分子场分析(CoMFA)和比较分子相似性指数分析(CoMSIA)将一系列91种结构多样的腺苷类似物用作训练集,这些类似物在腺嘌呤环的N6和C2位置以及核糖部分的3'、4'和5'位置有修饰。CoMFA和CoMSIA模型分别产生了显著的交叉验证q2值,分别为0.53(r2 = 0.92)和0.59(r2 = 0.92),并通过外部测试集(25种腺苷衍生物)进一步验证,每个模型的最佳预测r2值分别为0.84和0.70。CoMFA和CoMSIA的空间或疏水、静电和氢键相互作用图谱都很好地反映了先前通过分子对接获得的假定结合位点的性质。预计腺嘌呤环N6或C2位置的构象受限大基团以及5'位置的亲水和/或氢键基团会增加A3AR结合亲和力。N6处的小疏水基团促进受体激活。5'位置的亲水和氢键部分似乎有助于受体激活过程,这与跨膜结构域5、6和7的构象变化有关。3D-CoMFA/CoMSIA模型与先前的受体对接结果、当前A3AR激动剂的数据以及通过取代(在N6处)或构象限制(在5'-N-甲基脲酰胺处)将A3AR激动剂成功转化为拮抗剂的情况相关性良好。